Heart Failure

Responses from a study of in-person focus groups show that not only do patients report adverse effects on quality of life, physical well-being, and mental health but that their caregivers do as well.

In this Mendelian randomization study, higher odds of developing heart failure were seen in regular vs never smokers and in current vs former smokers.

Heart failure has been shown to be a contributing factor in more deaths in rural vs urban counties in which cardiovascular disease was pinpointed as the underlying cause of death.

Study results from Taiwan of patients with heart failure and comorbid chronic kidney disease show a drop in the risk of renal function decline among patients with heart failure with preserved ejection fraction (HFpEF) administered sacubitril/valsartan.

Merck and Johnson & Johnson (J&J) partner to produce J&J's COVID-19 vaccine; Anthony Fauci, MD, warns against shifting to a single-dose strategy for approved 2-shot vaccines; Medtronic recalls its HVAD Pump Implant Kits.

A comparison of patients with heart failure with preserved ejection fraction (HFpEF) randomized to 1 of 2 physical activities did not show a significant increase in peak oxygen consumption (VO2) vs guideline-based physical activity.

Compared with women with normotensive pregnancies, women who develop various hypertensive disorders during pregnancy have a greater risk of cardiac structure abnormalities in the decade after pregnancy.

Novartis' drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction.

An analysis of 30-year data on participants from the Augusta Heart study shows that Black individuals begin to exhibit potential signs of congestive heart failure earlier than their White counterparts.

A comparison of 2 time periods shows that following an initial decline, hospital admissions for primary management of heart failure rose between 2014 and 2017.

The program is closed with a discussion on how the coronavirus pandemic has affected the standard protocol for treating patients with heart failure.

Machine learning of data from 3 well-known heart studies shows a decline in heart failure risk from drinking at least 1 cup of caffeinated coffee each day.

Compared with a standard-protein diet, a high-protein diet reduced several markers of cardiometabolic risk in patients with heart failure and diabetes who were considered overweight or obese.

An early heart failure follow-up intervention succeeded in increasing referral to and completion of cardiology appointments within 7 days of discharge. The intervention was associated with lower risk of 30-day all-cause emergency department visits, all-cause hospitalizations, or death.

Expert physicians consider how novel agents will affect the treatment paradigm for heart failure.

An investigation of economic data from 3123 US counties, from 2007 to 2016, indicates that the cardiovascular mortality drop the authors saw may be a result of improved economic conditions.

A discussion on the optimal sites of care for patients with heart failure and how differing locations may alter treatment access.

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.

Women receiving treatment for early-stage breast cancer may have a lower risk of developing heart failure if their therapy regimens include statins.

A meta-analysis found evidence that different kinds of physical activity can help reduce risk of heart failure for the general population.

Both women and men have a greater chance of 90-day hospital readmission when they are considered to be in frail condition from heart failure.

A key opinion leader considers the optimal timing of adding an SGLT2 inhibitor to the treatment for patients with heart failure.

A discussion on the differences of sacubitril-valsartan and spironolactone for the treatment of heart failure.

A discussion on the promising findings from the TOPCAT study.

An expert in the management of heart failure considers the importance of recent findings from the PARALLAX study.